Botanix Pharmaceuticals (BOT) Q1 2027 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 TU earnings summary
27 Oct, 2026Executive summary
Sofdra shipments rose 5.3% QoQ to 35,130, while Q1 FY27 net revenue remained $10.1m and operating cash outflow fell 13% to $9.225m.
October cost actions target ~50% lower operating expenses for the rest of FY27, with an estimated ~75% of revenue-generating ability retained; this is not a revenue forecast.
Priorities include maximizing Sofdra revenue, global licensing and commercialization, complementary in-licensing, revised debt terms and evaluating broader transaction alternatives.
Financial highlights
Q1 FY27 Sofdra gross sales rose to $49.3m from $46.7m QoQ, while unaudited net revenue remained $10.1m.
Quarter-end cash and cash equivalents were $24.358m, down from $36.631m; inventory was ~$30.8m versus $31.3m in Q4 FY26.
Product-sales receipts increased 13% QoQ to $15.161m; net operating cash outflow declined to $9.225m from $10.6m.
Operating costs were $11.313m, down 1% QoQ, while manufacturing costs fell 35% to $0.8m from $1.2m.
Outlook and guidance
October actions target ~50% lower operating expenses for the remainder of FY27 versus Q1 FY27, with ~60% headcount reduction and estimated retention of ~75% of revenue-generating ability.
Remaining FY27 assumptions include ~$2m manufacturing costs, operating and staff costs flat, G&A flat, and gross-to-net payments tracking product sales.
Management expects gross-to-net improvement in Q2 FY27 if other factors remain constant; the annual US insurance deductible reset is expected to weigh temporarily on Q3 FY27 GTN.
Piramal API technology transfer is expected to reduce cost of goods sold by 25%–40%; completing the process is a priority.
Latest events from Botanix Pharmaceuticals
- Revenue up 487% to $33.8M, net loss narrowed, Sofdra prescriptions surged 527%.BOT
H2 2026 - Q4 FY26 saw 45% net revenue growth, 25% prescription growth, and improved cash flow.BOT
Q4 2026 TU - Record Sofdra growth, strong cash, and new API supply drive outlook despite tariff risks.BOT
Q3 2026 TU - FDA approval for Sofdra and robust capital raising position the company for US market launch.BOT
H2 2024 - Sofdra's US launch drove 857% revenue growth, but higher costs led to a $86.4M net loss.BOT
H2 2025 - Prescriptions and revenue soared, with $45M raised to fund growth and supply initiatives.BOT
H1 2026 - Net revenue up 28% and prescriptions up 24% as sales force and platform drive robust growth.BOT
Q2 2026 TU - Q4 net revenue hit $4.3M, prescriptions soared, and cash reserves grew to $64.9M.BOT
Q4 2025 TU - FDA-approved gel launches with digital-first strategy and broad coverage for rapid US growth.BOT
Investor Update